(57) reported that FGFR4 specific ASO treatment of mice with diet-induced obesity resulted in decreased FGFR4 expression in liver, leading to reduced body weight of obese mice by more than 20% and adiposity, as well as improved insulin sensitivity and liver steatosis. This evidence concerns the gene FGFR4 and fatty liver disease.